Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744340 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Phase 1 study, sponsored by howard safran.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01744340 is a Phase 1 study that has completed, run by howard safran. The registered enrollment target is 23 participants.
The verdict
NCT01744340, a Phase 1 study, has completed, sponsored by howard safran.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the full dose of eribulin mesylate can be safely given with the full dose of cetuximab. The activity of the combination of eribulin mesylate and cetuximab on recurrent head and neck cancer and colon cancer will also be assessed.
Interventions
- DRUG Head and neck
- DRUG Colon- Closed as of May 2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744340
The ClinicalTrials.gov registry entry for NCT01744340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is howard safran, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Head and neck is the first listed.
NCT01744340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744340 about?
NCT01744340 is a clinical study titled "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer". The purpose of this study is to determine if the full dose of eribulin mesylate can be safely given with the full dose of cetuximab. The activity of the combination of eribulin mesylate and cetuximab on recurrent head and neck cancer and colon cancer will also be assessed.
What is the current status of trial NCT01744340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01744340?
The interventions under investigation include: Head and neck (DRUG), Colon- Closed as of May 2014 (DRUG).
Who is sponsoring clinical trial NCT01744340?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.